BPC-157
Body Protection Compound-157
The Ground Truth Score
four plain questions, never one numberPromising, anecdote-led
Bottom line
Encouraging early human pilots and strong animal data, but no completed randomized trial in humans, and total human exposure remains tiny.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Advisory: yesRecommended, not legal yetAn FDA advisory committee recommended this for the 503A Bulks List in July 2026. Read that precisely: it is a recommendation, not a rule. Nothing changed about what is legal, FDA still has to run notice-and-comment rulemaking, and it can decline. Today this is still bought the same gray-market way it was in June.
Recommended for the 503A Bulks List by the FDA's Pharmacy Compounding Advisory Committee, 8-6, one abstention, at the July 23-24 2026 meeting. FDA's own briefing documents recommended against adding it. The vote is advisory and binds nothing.
Legal status as of 2026-07-24. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported ranges, not a protocol.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human trial has ever been completed. A Phase I trial (NCT02637284) was registered in 2016 and never reported results. The earliest documented human use is uncontrolled, a 2021 case series of 16 knee-pain patients from a single research group.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Speeds healing of tendon, ligament, muscle and gut tissue.
- Protects and repairs the GI lining, used for ulcers, reflux and IBD-type symptoms.
- No serious adverse events in the small number of humans studied so far.
- Reported to work locally when injected near an injury, and orally for the gut.
The data behind each bullet
What actually backs it
Speeds healing of tendon, ligament and muscle.
The healing data is overwhelmingly rodent. The only human signal is a 2021 case series. 16 knee-pain patients, 87.5% reporting meaningful relief at 6–12 months, with no placebo arm and no blinding. Encouraging, not controlled.
Lee & Padgett 2021 — knee-pain case series (uncontrolled, n=16) ↗Protects and repairs the gut lining.
A 2024 interstitial-cystitis pilot in 12 patients reported 80–100% symptom resolution, again uncontrolled. The mechanism rests on strong animal mucosal-protection and ulcer-healing data.
Lee et al. 2024 — interstitial-cystitis pilot (n=12) ↗No serious adverse events observed in humans.
A 2025 IV-safety pilot dosed two healthy adults up to 20 mg IV with no adverse events and no measurable change in cardiac, liver, kidney, thyroid or glucose markers. Reassuring, but n is roughly 30 across all human reports combined.
Lee & Burgess 2025 — IV safety pilot (n=2) ↗Works orally for gut-specific goals.
Oral use rests on animal data showing BPC-157 survives gastric acid and acts on the gut directly. No human oral pharmacokinetic data is published.
Xue et al. 2004 — intragastric BPC-157 heals gastric ulcer (rat) ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
No objective tracker exists — BPC-157's effect is local tissue repair, judged clinically (function, pain, imaging/endoscopy), not by any blood, wearable, or scan readout.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
BPC-157 acts locally at the injury/gut site via VEGFR2-driven angiogenesis and nitric-oxide signaling, with a plasma half-life under ~30 minutes; its effect is tissue repair at the site, not a systemic shift, so no analyte on a routine panel tracks whether it is working.
Read this before you spend on labs
Routine bloodwork cannot confirm BPC-157 is working. Its benefits are local tissue and gut healing plus subjective outcomes (pain, mobility, GI symptoms) that do not produce a measurable change in any orderable LabCorp/Quest panel. The only registered human data is a Phase I oral safety/PK trial in healthy volunteers (NCT02637284); it was designed to detect harm, not efficacy, and no routine analyte was validated as an efficacy readout. There is no independently replicated human efficacy evidence. Judge progress clinically (function, pain, imaging, endoscopy for GI cases), not by blood. Do not order a lab expecting it to prove response.
Bottom line
BPC-157 has no validated objective efficacy tracker in any modality. It acts locally at the injury or gut site via VEGFR2-driven angiogenesis and NO signaling, with a plasma half-life under ~30 minutes, so its effect is tissue repair at the site rather than a systemic shift that any analyte, wearable, CGM, DEXA, or scan would register. Human evidence is limited to a few small uncontrolled case series (tendon/ligament Grade D, gut Grade C) with no standardized objective outcome measures and no completed controlled trial. Track progress the same way the clinical data does: function, pain, range of motion, and where relevant imaging or endoscopy for the specific injury or GI lesion — not a number on a panel or a device. Anyone claiming a biomarker confirms it is guessing.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed, not proven in humans: BPC-157 appears to drive healing by upregulating VEGFR2, a receptor that triggers new blood-vessel growth, and nitric-oxide signaling, while protecting the gut lining. This is well-documented in animal cells and tissue; whether it does the same at these doses in people is untested.
Dosing & handling
What users and clinicians report
Reported ranges, not a protocol. Commonly cited: 250–500 mcg subcutaneously, once or twice daily, in 4–12 week cycles, injected near the area of injury; 500 mcg–1 mg orally for gut goals. Dr. Bakri's stated range is narrower and more conservative. 300–500 mcg, 2–3× per week for about 8 weeks, then 8–10 weeks off.
Dose magnitude is where people get hurt: a mislabeled or mis-reconstituted vial can put you 4–10× off target. These figures describe what users and one clinical authority report. They are not medical advice and not a prescription.
Timing & food
Commonly daily, often split AM/PM, injected near the injury for local goals or taken orally for the gut. No food-timing rule is established. The 'why' for frequent dosing is simply the minutes-long half-life, you re-dose to keep any exposure at all.
Half-life
Very short. Animal pharmacokinetics show a plasma half-life of roughly 5–30 minutes (no human PK exists at all), which is the stated rationale for daily or twice-daily dosing.
Reconstitution sensitivity
Fragile once mixed. Keep the reconstituted vial cold and dark, swirl (never shake), avoid heat, and replace the bacteriostatic water about every 28 days. The freeze-dried powder is far more stable than the solution.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
One of the most-discussed peptides, huge volume of dosing and recovery threads.
Consistency
Reports converge on tendon/joint and gut healing, but they're uncontrolled, and non-responders tend to get blamed ('you injected wrong' or 'bad product').
Source credibility
First-page search is affiliate funnels; the honest signal lives on independent logs (MESO-Rx) and skeptics framing it as 'n-of-1, wild west.'
- Tendon, joint, and soft-tissue recovery is the most-reported use, many describe faster return from nagging injuries.
- Gut, reflux, and IBD-type relief is the second big cluster of reports.
- Side effects are reported as rare and mild; the most common 'complaint' is simply 'I'm not sure it did anything.'
- Reports skew positive, but it's almost always run alongside rest, rehab, or other compounds, so clean attribution is rare.
Placebo risk, Moderate
Some users report objective injury resolution, but 'recovery feel' is subjective, so part of the benefit could be placebo. Measure where you can.
Risk panel
What could go wrong
Adverse events
None reported across roughly 30 humans studied. That total is far too small to detect anything but common, acute harms.
Theoretical concerns
BPC-157 upregulates VEGF and promotes angiogenesis, new blood-vessel growth, the same pathway tumors use to feed themselves. The leading clinical authority, Dr. Abud Bakri, advises cancer screening before use and warns against continuous indefinite dosing.
Contraindications
Active or suspected malignancy (theoretical angiogenesis risk). Untested in pregnancy.
Honest unknowns
No long-term human safety data of any kind. No controlled efficacy data. Optimal dose, route and cycling are all unestablished.
Confound watch
When someone credits BPC-157 for a recovery, ask what else changed. Most tendinopathies improve with rest and load management alone; many users simultaneously run TB-500, a structured rehab program, or TRT. The peptide almost never gets a clean attribution.
History
Discovery → first use → status
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: most of its recent appointees work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote recorded July 23-24, 2026; verified against FDA's meeting materials and contemporaneous reporting. Nothing here is final — check the current rule before acting.
FDA — PCAC meeting, July 23-24 2026 ↗- early 1990sIsolated and characterized from a protein in human gastric juice by Predrag Sikiric's group in Zagreb, still the primary BPC-157 research lineage.
- 2016Phase I human trial (NCT02637284) registered; no results ever posted.
- Sept 2023FDA places BPC-157 in Category 2, restricting bulk compounding.
- 2021–2025Three small uncontrolled human reports appear: knee pain (16), interstitial cystitis (12), IV safety (2).
- Apr 23 2026Removed from Category 2.
- Jul 23 2026PCAC voted 8-6 (1 abstention) to recommend BPC-157 for addition to the 503A Bulks List. Advisory only - FDA rulemaking still pending, and no evidence grade moves on a compounding vote.
Verification
The COA standard, applied
BPC-157 is injected, so demand a recent third-party Certificate of Analysis for the exact batch: HPLC purity ≥98%, mass-spec identity confirmation, and an LAL endotoxin result (endotoxin is invisible to HPLC and signals poor hygiene). Use an independent lab. Janoshik or Finnrick, never a vendor's in-house or vendor-recommended test. Replace bacteriostatic water every 28 days and refrigerate the reconstituted vial.
The full verification standard →Sources
Where this comes from
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.